A recent study showed that severe COVID-19 patients with primary thrombocythemia and IPF were significantly improved by the treatment of JAK1/2 inhibitor Ruxolitinib [36,37]. The gene discussed is JAK1; the disease is idiopathic pulmonary fibrosis.